Trial Profile
Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms QUATTROTURBO
- 01 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 10 Dec 2014 New trial record